When psoriatic arthritis symptoms are under control, you may be tempted to stop taking medication. Here’s why that’s a bad idea.

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more ...

Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

This review discusses the features of oligoarticular, polyarticular, systemic, and psoriatic JIA and enthesitis-related ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

Discover effective treatments for psoriatic arthritis, with expert tips on managing symptoms, reducing inflammation, and improving joint health for a better quality of life.

Michaela Hagenhofer, General Manager, Commercial Operations at Johnson & Johnson Innovative Medicine, explains how J&J is ...

Racial and ethnic diversity is lacking in PsA clinical trials, with non-White participants remaining severely underrepresented.

Zentiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...

It is indicated for various diseases including heumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...

Lupin and Zentiva partner to commercialize Certolizumab Pegol biosimilar globally, sharing profits and investing in ...